Ranolazine API

Name	Ranolazine
Chinese name	雷诺嗪
Cas Number	95635-55-5
Source	India
Qualifications	USDMF/-/-/-/-

Ranolazine is a new type of fatty acid oxidase inhibitor. Under ischemic conditions, the blood flow of the myocardium is distributed to the ischemic area, which can reduce intracellular calcium overload and relieve the symptoms of angina. It was approved by the US FDA in 2006 as a first-line treatment for symptomatic patients with chronic angina. Clinical results show that ranolazine can be used as a single treatment or as an auxiliary drug for other anti-angina pectoris treatments. For chronic stable angina pectoris, it can relieve symptoms and improve exercise tolerance. Unlike existing anti-angina drugs, ranolazine is a partial fatty acid oxidase inhibitor, which has no effect on heart rate and blood pressure. It can effectively relieve angina without changing other kinetic parameters of the drug, and can improve the quality of life of patients with angina. Ranolazine is the recommended drug for the treatment of angina in relevant foreign guidelines and has a good clinical prospect. There are more patients with angina, and the market prospect of ranolazine is good.

Hot Tags: ranolazine api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Dimethyl Fumarate API, Apremilast API, Lifitegrast API, Teriflunomide API, Gabapentin API, Ulipristal Acetate API

• Previous: Cinacalcet Hydrochloride API
• Next: Pazopanib Hydrochloride/Pazopanib API